The Joint Corp. (JYNT) Market Cap
The Joint Corp. has a market capitalization of $118.2M.
Price: $8.29
▼ -0.08 (-0.96%)
Market Cap: 118.18M
NASDAQ · time unavailable
CEO: Sanjiv Razdan
Sector: Healthcare
Industry: Medical - Care Facilities
IPO Date: 2014-11-11
Website: https://www.thejoint.com
The Joint Corp. (JYNT) - Company Information
Market Cap: 118.18M|Sector: Healthcare
Company Profile
The Joint Corp. specializes in the establishment, proprietorship, operation, and overall administration of chiropractic treatment centers. Its business operations are structured into two main divisions: corporate-owned clinics and franchised facilities. The firm employs several strategic models for its expansion and day-to-day functioning, which include direct company ownership, various management agreements, licensing its brand to franchisees, and collaborating with regional development partners. As of March 1, 2022, the company maintained approximately 700 active locations throughout the United States. Founded in 2010, The Joint Corp. maintains its primary corporate headquarters in Scottsdale, Arizona.
Analyst Sentiment
From 4 Active Polls
1Y Forecast: $20.00
▲ +141.3% Potential Upside
Consensus Target Metrics
Low Bound
$20
Median
$20
High Bound
$20
Average
$20
Price & Moving Averages
🎯 Wall Street Analyst Intelligence Report
1-Year structural target targets, chart projections, and sentiment maps.
Consensus Trend Projection
Trailing closures vs. 12-month metrics map.
Analyst Vote Distribution
Aggregate institutional coverage sentiment weights.
📊 Historical Valuation Multiples
Real-time Trailing Twelve Month (TTM) momentum side-by-side with discrete quarterly metrics.
| Fiscal Quarter | TTM | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|---|---|---|
| Period Ending | Trailing 12M | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 |
| Market Cap ($M) | 118 | 126 | 127 | 146 | 177 | 190 | 159 | 171 | 197 |
| Enterprise Value ($M) | 99 | 106 | 105 | 118 | 149 | 170 | 134 | 160 | 194 |
| Price to Earnings Ratio (P/E) | 37.44 | 24.15 | 32.06 | 42.82 | 472.95 | 59.14 | -14.76 | -13.62 | -13.75 |
| Price/Earnings-to-Growth Ratio (PEG) | — | — | 2.40 | 51.46 | 321.00 | 0.44 | — | -0.10 | -3.94 |
| Price to Sales Ratio (P/S) | 2.09 | 8.47 | 8.37 | 10.94 | 13.33 | 14.50 | -4.14 | 5.67 | 15.65 |
| Price to Book Ratio (P/B) | 7.60 | 8.11 | 8.44 | 6.45 | 7.61 | 9.53 | 7.68 | 8.37 | 8.51 |
| Price to Free Cash Flow Ratio (P/FCF) | 44.49 | -73.36 | 49.85 | 100.60 | 486.42 | -47.04 | 41.24 | 53.41 | -159.68 |
| Enterprise Value to Sales (EV/Sales) | — | 7.16 | 6.95 | 8.80 | 11.25 | 13.00 | -3.51 | 5.29 | 15.38 |
| Enterprise Value to EBITDA (EV/EBITDA) | 33.56 | 70.25 | 76.19 | 154.19 | -208.91 | -589.81 | -112.48 | 85.99 | -761.04 |
| Debt to Equity Ratio | -6.59 | 0.13 | 0.13 | 0.09 | 0.09 | 0.11 | 0.04 | 0.46 | 0.61 |
📰 Market News & Coverage
15 Stories AvailableReal-time institutional reporting and market updates for JYNT.
Grid Metals Announces TSX Venture Approval for Falcon West Cesium Project Joint Venture
TORONTO, ON / ACCESS Newswire / July 31, 2026 / Grid Metals Corp. (TSXV:GRDM)(OTCQB:MSMGF) ("Grid" or the "Company") is pleased to announce it has received conditional approval from the TSX Venture Exchange ("TSXV") for its previously announced transaction with Avenir Minerals Limited ("Avenir"), a wholly-owned subsidiary of Agnico Eagle Mines Limited, for a joint venture on the Company's Falcon West Cesium Property (the "Property") located in southeastern Manitoba, Canada as announced by the Company on July 20, 2026. Under the joint venture agreement (the "JV Agreement") between the Company and Avenir, Avenir has acquired an initial 15% interest in the Property and resulting joint venture for C$3,750,000 in cash and will thereafter fund its pro rata share of costs.
Namibia Critical Metals Announces Completion of Japan's C$23 Million Earn-In and Formation of Strategic Joint Venture Company for the Lofdal Heavy Rare Earth Project
Japan's Strategic Investment Advances Lofdal to Next Phase of Development with Non-Dilutive Pre-FID Project Funding Halifax, Nova Scotia--(Newsfile Corp. - July 30, 2026) - Namibia Critical Metals Inc. (TSXV: NMI) (OTCQB: NMREF) ("Namibia Critical Metals" or the "Company" or "NCMI") is pleased to announce that Japan Organization for Metals and Energy Security ("JOGMEC") and Toyota Tsusho Corporation ("Toyota Tsusho" or "TTC") have established TJ Namibia Rare Earths Corporation ("TJNREC"), the jointly owned special purpose company that will hold Japan's 50% participating interest in the Lofdal Heavy Rare Earth Project ("Lofdal" or the "Project"). Concurrent with the establishment of TJNREC, Japan has completed its previously announced C$23 million earn-in commitment under the Joint Venture Agreement through funding of the approximately C$11 million expanded Definitive Feasibility Study ("DFS") budget approved on July 10, 2026.
The Joint Chiropractic Earns Entrepreneur Recognition as a Premier Multi-Unit Franchise Investment
Top Brands for Multi-Unit Owners honor underscores continued momentum of nation's largest chiropractic franchise as experienced operators seek scalable healthcare investments SCOTTSDALE, Ariz., July 30, 2026 /PRNewswire/ -- The Joint Corp. (NASDAQ: JYNT), the nation's largest franchisor of chiropractic care through The Joint Chiropractic® network, has been recognized by Entrepreneur as one of its Top Brands for Multi-Unit Owners for 2026, further validating the brand's position as one of franchising's premier growth opportunities for experienced multi-unit and multi-brand investors.
3D Systems' Saudi Arabian Joint Venture NAMI Obtains Critical Military Manufacturing License for Local Defense Hardware Production
GAMI manufacturing license advances NAMI's role in defense localization and supports critical infrastructure resilience in the Kingdom ROCK HILL, S.C., July 29, 2026 (GLOBE NEWSWIRE) -- 3D Systems (NYSE:DDD) today announced that the National Additive Manufacturing and Innovation Company (NAMI) has been granted a Military Manufacturing License by the General Authority for Military Industries (GAMI) of Saudi Arabia.
Borr Drilling Limited - Completes Acquisition of Five Rigs Through New Joint Venture
HAMILTON, Bermuda, July 29, 2026 /PRNewswire/ -- Borr Drilling Limited (NYSE: BORR) (OSE: BORR) ("Borr Drilling" or the "Company") today announced that BC Ventures Limited ("BC Ventures"), a 50/50 joint venture between the Company and its long-term well construction partner in Mexico, has completed the previously announced acquisition of five premium jack-up rigs from Fontis Finance Ltd. for a total purchase price of $287 million.
Co-Diagnostics Joint Venture CoSara Provides Ebola Test Kits for Analytical Studies
Company also completes proof of concept for the first blood-borne test for Ebola on Co-Dx PCR Pro ® instrument SALT LAKE CITY, July 28, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that CoSara Diagnostics Pvt. Ltd. ("CoSara"), the Company's joint venture in India, has sent test kits of the SARAGENE® Bundibugyo Virus Test to a third-party laboratory for evaluation following a request by the India Centre for Cellular and Molecular Platforms ("C-CAMP"), an initiative supported by the India Department of Biotechnology.
EagleNXT Joint Venture “ThirdEye USA” Selected to Participate in EXTiC 26-2 Counter-UAS Experimentation Event
ThirdEye USA Selected to Demonstrate Counter-UAS System during exercise ALLEN, Texas, July 27, 2026 (GLOBE NEWSWIRE) -- AgEagle Aerial Systems Inc. (dba, EagleNXT) (the “Company” or “EagleNXT”) (NYSE: UAVS), a leading provider of full-stack drone, sensor, counter-drone, and software solutions for defense, government, and commercial applications worldwide, today announced their joint venture “ThirdEye USA” has been selected to participate in next month's Experimentation: Transforming in Contact (EXTiC) 26-2 (“EXTiC 26-2”), a key U.S. Central Command (CENTCOM) technology experimentation initiative. CENTCOM, in collaboration with the Defense Innovation Unit (DIU), has issued an open call for new and emerging technologies that align with its strategic priorities.
VERAXA Biotech Announces Advancement of Novel Bispecific Antibody Drug Conjugate Program VXA-222 from Joint Discovery Collaboration with OmniAb
VERAXA Biotech's and OmniAb's bispecific ADC program VXA-222 advances into next phase at VERAXA following the achievement of a key technical milestone.
Verizon Revenue Ticks Down, Profit Falls on Joint-Venture Costs
Verizon Communications gained a net 184,000 postpaid phone connections in the second quarter, beating Wall Street's expectations on a metric that gauges new lucrative customers.
The Joint Corp. to Report 2026 Second Quarter Results on Thursday, August 6 and Host Conference Call and Webcast
SCOTTSDALE, Ariz., July 23, 2026 (GLOBE NEWSWIRE) -- The Joint Corp. (NASDAQ: JYNT), the nation's largest franchisor of chiropractic care through The Joint Chiropractic ® network, announced it will report its 2026 second quarter financial results on Thursday, August 6, 2026, after the market close and host a conference call and simultaneous webcast at 5:00 p.m. ET that day. During the call, The Joint Corp. President and CEO Sanjiv Razdan and CFO Scott Bowman will review the Company's financial results and provide a business update, followed by a question-and-answer session.
Rush Enterprises and MCT Companies to Form Strategic Joint Venture
NEW BRAUNFELS, Texas and OMAHA, Neb., July 23, 2026 (GLOBE NEWSWIRE) -- Rush Enterprises, Inc. (NASDAQ: RUSHA & RUSHB), which operates the largest network of commercial vehicle dealerships in North America, today announced that it has signed an agreement to form a joint venture with MCT Companies, one of the largest Carrier Transicold dealers in the United States.
Liberty Energy and PowerBridge Form Strategic Joint Venture to Support Powered Data Center Campus Development
DENVER & HOUSTON--(BUSINESS WIRE)--Liberty Energy Inc. (NYSE: LBRT) ("Liberty") and PowerBridge LLC ("PowerBridge") today announced the formation of a strategic joint venture (“JV”) that leverages PowerBridge's digital campus development assets and operating platform with the integrated power generation, energy management, and operational capabilities of Liberty Power Innovations ("LPI"), a Liberty Energy company. The JV's current scope is expected to support a planned 2 gigawatt (“GW”) powered.
Co-Diagnostics Joint Venture CoSara Initiates Clinical Studies in India for Tuberculosis Test on PCR Platform
PCR Pro Instruments and MTB Test Kits Now Deployed to Select Labs Across India SALT LAKE CITY, July 22, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that CoSara Diagnostics Pvt. Ltd. ("CoSara"), the Company's joint venture in India, is initiating clinical studies for the tuberculosis test on the CoSara PCR Pro ® instrument.
DirectBooking Technology and DeepYou Form Joint Venture to Establish AI Robotics Travel and Hospitality Company
HONG KONG, July 21, 2026 (GLOBE NEWSWIRE) -- DirectBooking Technology (NASDAQ: ZDAI) (“DirectBooking” or the “Company”) today announced that it has entered into a strategic joint venture agreement with Beijing DeepYou Digital Technology Co., Ltd. (“DeepYou”).
Joint Statement from Avis Budget Group and Pentwater Capital Management
PARSIPPANY, N.J. and NAPLES, Fla.
📊 AI Financial Analysis
Powered by StockMarketInfo"JYNT reported Q1’26 revenue of $14.82M and net income of $1.30M (EPS $0.09). Versus Q1’25, revenue increased from $13.08M to $14.82M (+13.4% YoY) and net income rose from $0.97M to $1.30M (+34.3% YoY). Sequentially, revenue edged down from $15.17M in Q4’25 to $14.82M (-2.3% QoQ), while net income declined from $0.99M to $1.30M (+31.1% QoQ). Profitability improved meaningfully across the quarter-to-quarter trend. Gross margin expanded to 84.7% in Q1’26 (vs. 70.6% in Q4’25), and net margin rose to 8.8% (vs. 6.5% in Q4’25). Operating income also strengthened to $0.87M (5.9% margin) from $0.75M (4.9%). Cash flow quality was mixed: operating cash flow was -$1.48M and free cash flow was -$1.71M in Q1’26, despite positive accounting earnings, implying working-capital/non-cash impacts. Balance sheet remains liquid with cash & equivalents of $20.7M and net cash (net debt -$18.6M), though total assets and equity declined QoQ. Shareholder returns are moderately positive on momentum not supported here: the stock is down -7.98% over 1 year, with no dividend; buybacks are visible in cash flow (repurchase activity), but total shareholder return is constrained by negative 1Y price change. Analyst consensus target (~$20) suggests substantial upside from the $9.22 context price."
Revenue Growth
Revenue grew +13.4% YoY ($13.08M to $14.82M) but slipped -2.3% QoQ ($15.17M to $14.82M), showing a slowing sequential trend.
Profitability
Net income up +34.3% YoY to $1.30M; net margin improved to 8.8% from 6.5% in Q4. Gross margin expanded sharply to 84.7% (from 70.6%), indicating margin recovery.
Cash Flow Quality
Despite strong net income, Q1’26 operating cash flow was -$1.48M and free cash flow -$1.71M, indicating earnings are not converting to cash in the latest quarter.
Leverage & Balance Sheet
Liquidity is solid with $20.7M cash and net cash position (net debt -$18.6M). However, total assets and equity both declined QoQ, and retained earnings remain deeply negative.
Shareholder Returns
1Y price change is -7.98% (no >20% momentum tailwind). No dividends; buyback activity appears in cash flow, but total return is tempered by weak 1Y performance.
Analyst Sentiment & Valuation
Consensus target is $20 vs. $9.22 context price, implying meaningful upside (though the stock’s trailing multiples are elevated).
Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.
Fundamentals Overview
JYNT delivered strong transformation-driven profitability in Q1 2026 while macro conditions continued to pressure demand. Revenue from continuing operations grew 13% to $14.8M and adjusted EBITDA from continuing operations surged to $2.2M versus $46K a year ago, with net income swinging to $1.1M. System-wide sales fell 4.9% and comps were -4.2%, but management emphasized a steady sequential improvement in active members (4 consecutive months) and expects comp trends to improve through 2026 (slightly negative in Q2, positive in Q3/Q4). The key operational catalyst is refranchising: the company-owned/managed footprint has been reduced from 135 at the start of Joint 2.0 to 75 at quarter end, with sales agreements (March LOI for 5, April APAs for 45 Southern California) targeting only 3 remaining company-operated clinics after lease assignments transfer. Pricing and retention initiatives (3-month minimum terms, Align One) are positioned to support unit economics and conversion without patient pushback. Guidance was reiterated.
Growth Catalysts
- Refranchising momentum: company-owned/managed clinics reduced to 75 at quarter end from 135 at start of Joint 2.0; only 3 expected to remain company-operated after pending sales close
- Sequential improvement in active member count per clinic: 4 consecutive months of month-on-month improvement starting in January
- Pricing optimization: $5 to $10 price increases rolled out across ~300 clinics; expected enterprise-wide rollout beginning in Q3
- CareCredit national rollout enabling deferred payments on higher-ticket packages and plans; provides access to 12 million members
- New sales initiative tests: first B2B partnership program offering partner employees access to care; 3-month minimum term commitment program and more flexible offerings to lift conversion/retention
- Digital visibility improvements: AI visibility score improved to 78–80 from ~70; all local clinic microsites migrated to new optimized template; higher organic traffic and lead quality
Business Development
- Southern California agreement to sell 45 company-owned/managed clinics (asset purchase agreement signed April; $2.3 million total)
- March 2026 letter of intent to sell 5 company-owned/managed clinics
- Additional signed refranchising agreements pending closing (2 other refranchising agreements referenced as pending closing; combined with April and March transactions leave 3 clinics remaining)
- Buyback of 3 regional developer (RD) territories to capture more long-term royalty economics
- First B2B partnership program: partner employees get access to care at The Joint (partner name not disclosed in transcript)
- CareCredit program roll out nationwide (program sponsor not disclosed in transcript)
Financial Highlights
- Continuing operations revenue grew 13% YoY to $14.8M
- Adjusted EBITDA from continuing operations increased to $2.2M vs $46K in Q1 2025 (large year-over-year operating leverage)
- Net income from continuing operations was $1.1M vs net loss of $506K in Q1 2025
- Free cash flow improved $2.3M vs prior year period (driven by $2.2M improvement in operating cash flow)
- System-wide sales declined 4.9% YoY to $126M; comp sales were -4.2%
- Cost of revenue down 8% to $2.7M YoY, primarily due to lower regional developer royalties
- Selling & marketing up 6% to $3.7M (transition-related); G&A up 2% to $7.1M, including ~$300K nonrecurring items not expected post-refranchising
- Full-year gross margin model target post-refranchising: 83%–85% vs 90% in 2025; G&A as % revenue expected 40%–42% vs 64% in 2025; CapEx ~3% of revenues; free cash flow conversion 60%–70%; implied adjusted EBITDA margin 19%–21% and net income margin 13%–15%
Capital Funding
- Share repurchases: repurchased ~137,000 shares for $1.1M at average $8.35/share
- Remaining authorization: $4.5M under the $12M authorization approved Nov 2025
- Revolver: $20M line of credit with JPMorgan Chase, fully undrawn, available through Aug 2029 (maturity extended by 2 years from Aug 2027 to Aug 2029)
- RD territory buybacks: completed 3 RD buybacks; expected annualized reduced RD royalties of ~$450,000 (partially offset by internal territory management costs)
Strategy & Ops
- Joint 2.0 transformation milestone: refranchising effectively complete; only ~3 company-owned/managed clinics expected to remain after lease assignments transfer in next couple of months
- Lease assignment mechanics: closing timing dependent on lease transfers to new owners; management expects near-completion of lease assignment process within the next couple of months
- Clinic portfolio optimization: Q1 opened 3, closed 20; franchise clinics 868 and company-owned/managed 75 at quarter end
- Enhanced preopening protocols: driving faster time to breakeven for new clinic openings
- Marketing mix shift: $500 per clinic per month reallocated from local marketing to national advertising late 2025
- Contract/retention changes: extended minimum contract term from 2 to 3 months with 0 patient pushback
- New retention offering: Align One wellness plan ($35–$39/month depending on region; 1 visit/month with ability to buy incremental visits); uptake results cited as closer to 2 visits/month and significantly lower attrition
Market Outlook
- Reiterated full-year 2026 guidance: system-wide sales $519M–$552M; comp sales -3% to +3%; consolidated adjusted EBITDA $12.5M–$13.5M; new franchise clinic openings 30–35
- Comp cadence expectation: slightly negative comps in Q2, positive comps in Q3 and Q4, with Q4 expected higher than Q3
- Adjusted model start: expect pure-play franchisor model benefits starting back half of 2026 (not long-term targets)
- Enterprise pricing rollout: expect roll-out of pricing optimization to the rest of the portfolio beginning in Q3; management referenced pricing to kick in early Q3 for unit economics stabilization
Risks & Headwinds
- Macro headwinds impacting traffic and demand: management cited general cost-of-living pressures contributing to -4.2% comp sales in Q1
- Remaining refranchising execution risk: lease assignments must be reassigned to new owners for full deal conclusion; timing could slip if lease assignments lag
- Unit economics sensitivity: gross margin target post-refranchising is lower percentage (83%–85%) than 2025 (90%), implying franchise transition changes could affect profitability mix
- Developer/royalty economics: continued reliance on transferring away from regional developer royalties (currently benefited from lower RD royalties in cost of revenue)
Q&A: Analyst Interest
- Topic: Timing and remaining execution risk on refranchising closings: Management explained that closure hinges on lease assignment to new owners. They guided that within the next couple of months the lease process should be near completion, with all but 6–7 clinics already operated by buyers or via management-services economics.
- Topic: Same-store sales turnaround drivers (comp improvement path): Management cited work started late last year: pivot to pain-relief messaging, shifting $500 per clinic per month from local to national marketing, and improved SEO/AI visibility. They added retention levers: extended minimum terms to 3 months, and Align One plan lowering attrition.
- Topic: Forward run-rate and cost structure after refranchising: Management addressed post-refranchise SG&A/G&A by saying the majority of the new model effect appears in the back half of 2026. They noted Q1 included ~$300K nonrecurring items tied to continuing operations that should disappear after refranchising, and a restructuring charge mostly flowed through G&A.
Sentiment: POSITIVE
Note: This summary was synthesized by AI from the JYNT Q1 2026 earnings transcript. Financial data is complex; please verify all metrics against official SEC filings before making investment decisions.
📋 Official Regulatory 10-K / 10-Q SEC Filings
Direct authenticated documentation links to audited SEC database reports for JYNT.